Literature DB >> 17869370

Omega 3 - Omega 6: What is right for the liver?

Ashraf Mohammad El-Badry1, Rolf Graf, Pierre-Alain Clavien.   

Abstract

Linoleic and alpha-linolenic acids are the fatty acids designated as "essential" since they are not synthesized by mammalian cells and must be provided in the diet. The recent dietary shift towards the consumption of n-6 (omega-6) at the expense of n-3 (omega-3) polyunsaturated fatty acids (PUFAs) is thought to be a primary cause of many diseases related to the Western diet. The body converts linoleic acid to arachidonic acid and derives eicosapentaenoic acid from alpha-linolenic acid. Ideally the effects of these fatty acids and their eicosanoid derivatives are tailored to the specific biological needs of the body. The balance between n-3 and n-6 PUFAs is essential for metabolism and maintenance of the functions of both classes. The availability of n-3 long chain PUFAs plays a major role in regulating both fat accumulation and its elimination by the liver. Derangement of hepatic n-6:n-3 PUFA ratio impacts on the histological pattern of fatty liver through modulation of the amount of intrahepatic lipids. Moreover, the influence of PUFAs and their eicosanoid products on hepatic microcirculation and ischemia/reperfusion injury has been demonstrated in many studies. This concise review article will focus on the role of PUFAs and eicosanoids in hepatic steatosis, microcirculation and ischemia/reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869370     DOI: 10.1016/j.jhep.2007.08.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  50 in total

Review 1.  Nutrition and nonalcoholic fatty liver disease in children.

Authors:  Miriam B Vos; Craig J McClain
Journal:  Curr Gastroenterol Rep       Date:  2008-06

Review 2.  Pharmacological agents for NASH.

Authors:  Vlad Ratziu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-10-15       Impact factor: 46.802

3.  Nutrition and nonalcoholic fatty liver disease in children.

Authors:  Miriam B Vos; Craig J McClain
Journal:  Curr Diab Rep       Date:  2008-10       Impact factor: 4.810

4.  Quantifying conversion of linoleic to arachidonic and other n-6 polyunsaturated fatty acids in unanesthetized rats.

Authors:  Fei Gao; Dale Kiesewetter; Lisa Chang; Stanley I Rapoport; Miki Igarashi
Journal:  J Lipid Res       Date:  2010-07-09       Impact factor: 5.922

5.  Omega-3 long chain polyunsaturated Fatty acids for treatment of parenteral nutrition-associated liver disease: a review of the literature.

Authors:  Emma M Tillman; Richard A Helms
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

Review 6.  Modulation of hepatic steatosis by dietary fatty acids.

Authors:  Alessandra Ferramosca; Vincenzo Zara
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

7.  Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis.

Authors:  Priya Handa; Bryan D Maliken; James E Nelson; Vicki Morgan-Stevenson; Donald J Messner; Barjinderjit K Dhillon; Heather M Klintworth; Mary Beauchamp; Matthew M Yeh; Clinton T Elfers; Christian L Roth; Kris V Kowdley
Journal:  Hepatology       Date:  2014-05-27       Impact factor: 17.425

8.  Classification of genes and putative biomarker identification using distribution metrics on expression profiles.

Authors:  Hung-Chung Huang; Daniel Jupiter; Vincent VanBuren
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

9.  Biliary Polyunsaturated Fatty Acids and Telocytes in Gallstone Disease.

Authors:  Artur Pasternak; Jolanta Bugajska; Mirosław Szura; Jerzy A Walocha; Andrzej Matyja; Mariusz Gajda; Krystyna Sztefko; Krzysztof Gil
Journal:  Cell Transplant       Date:  2016-08-05       Impact factor: 4.064

Review 10.  Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease.

Authors:  Manoela Mota; Bubu A Banini; Sophie C Cazanave; Arun J Sanyal
Journal:  Metabolism       Date:  2016-03-03       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.